10.3 Metabolic Syndrome and Cardiometabolic Risk

What Metabolic Syndrome Is, and the Exact Numbers

Metabolic syndrome is a clustering of interrelated cardiometabolic abnormalities that roughly doubles the risk of atherosclerotic cardiovascular disease (ASCVD) and increases the risk of incident type 2 diabetes about fivefold. It affects roughly one in three United States adults and more than half of adults over 60. On the CMC exam it appears as a risk-stratification and patient-education item: you are expected to recognize the cluster in a bedside chart, quantify the risk, and drive the discharge plan.

The harmonized definition (National Cholesterol Education Program ATP III as updated by AHA/NHLBI and the 2009 joint statement) requires any 3 of the following 5 criteria:

Two traps live in this table. First, "on therapy" satisfies the criterion: a patient whose blood pressure is 118/70 on lisinopril still meets the blood-pressure criterion, and a patient with a triglyceride level of 96 mg/dL on fenofibrate still meets the triglyceride criterion. Second, the waist thresholds are population-specific. The International Diabetes Federation uses lower cut points for people of South Asian, Chinese, Japanese, and other Asian ancestry — 90 cm in men and 80 cm in women — so a normal-BMI South Asian patient can be centrally obese by any clinically meaningful standard while falling below the 102/88 cm values.

Measure the waist correctly: a horizontal tape at the top of the iliac crest, snug without compressing, read at the end of a normal expiration. A waist measured over a gown, at the umbilicus of a pendulous abdomen, or after a deep breath is not a usable data point.

Pathophysiology in one pass

Metabolic syndrome is driven by visceral adiposity and insulin resistance. Visceral adipose tissue is an endocrine organ that drains into the portal circulation. Its excess lipolysis floods the liver with free fatty acids, which worsens hepatic insulin resistance and drives overproduction of very-low-density lipoprotein. At the same time the adipose secretory profile shifts: adiponectin (insulin-sensitizing, anti-inflammatory) falls while leptin, tumor necrosis factor alpha, interleukin-6, and resistin rise. The consequences are the ones the cardiac nurse sees:

• Atherogenic dyslipidemia: high triglycerides, low HDL, and a shift toward small dense LDL particles. LDL cholesterol may look unimpressive while particle number is high, which is why non-HDL cholesterol (total minus HDL, target generally 30 mg/dL above the LDL goal) and apolipoprotein B are better risk markers in this population than LDL-C alone.
• Prothrombotic state: elevated plasminogen activator inhibitor-1 and fibrinogen, impaired fibrinolysis.
• Pro-inflammatory state: elevated high-sensitivity C-reactive protein.
• Vascular effects: endothelial dysfunction with reduced nitric oxide bioavailability, sympathetic activation, adipose-tissue renin-angiotensin-aldosterone activation, and sodium retention that make hypertension harder to control.

The conditions that travel with it

• Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly non-alcoholic fatty liver disease) — the hepatic manifestation of the same physiology, and an independent ASCVD risk marker.
• Obstructive sleep apnea — screen with STOP-BANG; untreated OSA is a leading cause of resistant hypertension, nocturnal angina, and atrial fibrillation recurrence after cardioversion or ablation.
• Polycystic ovary syndrome — insulin resistance in reproductive-age women, with its own long-term ASCVD risk.
• Chronic kidney disease and albuminuria — a urine albumin-to-creatinine ratio above 30 mg/g is both a consequence and an independent risk multiplier.
• Hyperuricemia and gout, erectile dysfunction (an early marker of endothelial disease), and heart failure with preserved ejection fraction.

Quantifying Risk

Do not stop at "the patient has metabolic syndrome." Quantify.

• Pooled Cohort Equations estimate 10-year ASCVD risk in adults 40 to 75 without established disease: low below 5 percent, borderline 5 to 7.4 percent, intermediate 7.5 to 19.9 percent, high 20 percent or above. Intermediate risk is where the shared decision-making conversation lives.
• PREVENT (Predicting Risk of cardiovascular disease EVENTs, AHA 2023) is the newer tool. It estimates 10-year and 30-year risk, starts at age 30, includes heart failure as an outcome, incorporates estimated glomerular filtration rate, and optionally urine albumin-to-creatinine ratio, hemoglobin A1c, and a social deprivation index. It generally produces lower absolute risk estimates than the Pooled Cohort Equations.
• Coronary artery calcium (CAC) scoring is the best available risk refiner when the decision about statin therapy is genuinely uncertain at intermediate risk. A CAC of 0 supports deferring statin therapy in a patient without diabetes, without a strong family history, and who does not smoke ("the power of zero"). CAC 1 to 99 favors statin therapy, particularly at age 55 or older. CAC 100 or above, or at or above the 75th percentile for age, sex and ethnicity, supports statin initiation.
• Risk enhancers that push a borderline or intermediate patient toward treatment: family history of premature ASCVD, persistent LDL-C 160 mg/dL or higher, chronic kidney disease, metabolic syndrome itself, chronic inflammatory disease, South Asian ancestry, history of preeclampsia or premature menopause, persistent triglycerides 175 mg/dL or higher, lipoprotein(a) 50 mg/dL or higher, apolipoprotein B 130 mg/dL or higher, ankle-brachial index below 0.9, and high-sensitivity C-reactive protein 2.0 mg/L or higher.

Managing the Cluster

There is no drug for "metabolic syndrome." You treat each component and you treat the adiposity that drives all five.

Lifestyle intervention with actual targets

• Weight loss of 5 to 10 percent of body weight improves every component. In the Diabetes Prevention Program, a 7 percent weight loss with 150 minutes of activity per week reduced progression to type 2 diabetes by 58 percent — more than metformin did.
• 150 minutes per week of moderate-intensity aerobic activity (or 75 minutes vigorous), spread over most days, plus resistance training on 2 or more days per week. Breaking up prolonged sitting has independent benefit.
• Dietary pattern over single nutrients: Mediterranean or DASH patterns, sodium below 2,300 mg daily with an ideal target of 1,500 mg for hypertension, minimal added sugar and sugar-sweetened beverages, replacement of saturated with unsaturated fat, and increased fiber.
• Smoking cessation, alcohol limited to 2 drinks daily for men and 1 for women, and 7 to 9 hours of sleep with treatment of diagnosed sleep apnea.

Pharmacotherapy by component

Obesity pharmacotherapy and surgery

The obesity drugs are now cardiovascular drugs, and CMC candidates should know the headline outcome data:

• Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by about 20 percent in patients with overweight or obesity and established cardiovascular disease without diabetes (SELECT), and improved symptoms and exercise capacity in obesity-related HFpEF (STEP-HFpEF).
• Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced weight loss of roughly 20 percent in SURMOUNT-1 and reduced heart-failure events while improving quality-of-life scores in obesity-related HFpEF (SUMMIT).
• Nursing implications: dose escalation is slow and deliberate to limit nausea; delayed gastric emptying raises aspiration concern around sedation and intubation; injection technique, storage, and refill/cost barriers dominate adherence; and rapid weight loss requires reassessment of antihypertensive, diuretic, and insulin doses.
• Metabolic and bariatric surgery is indicated at a BMI of 35 kg/m2 or more, or 30 or more with type 2 diabetes, and produces durable weight loss with reduced macrovascular events.
• Cardiac rehabilitation is a class I recommendation after ACS, PCI, CABG, and in chronic HFrEF, and reduces cardiovascular mortality — yet only about a quarter of eligible patients ever enroll. Referral placed before discharge, with the first appointment scheduled, is the single most effective driver of enrollment and is squarely a nursing responsibility.

Health equity and the nurse's role

Cardiometabolic risk tracks with the social determinants of health: food insecurity and limited access to fresh food, neighborhoods without safe places to walk, shift work and sleep disruption, insurance status, medication cost (GLP-1 agonists in particular), transportation to cardiac rehabilitation, health literacy, and structural racism. PREVENT explicitly incorporates a social deprivation index because these factors change outcomes. Practical nursing actions: screen for food and medication insecurity in plain language, involve social work and pharmacy for assistance programs before discharge rather than after a refill fails, and check that rehabilitation is geographically and financially reachable.

Use motivational interviewing rather than instruction. Ask permission before giving information, use open questions, affirm, reflect, and summarize, elicit the patient's own reasons for change, and resist the "righting reflex" — correcting the patient generates resistance and argument rather than behavior change. Close with a teach-back confirmation, a reconciled medication list, follow-up within 7 days, and a written plan that names one or two concrete, measurable behaviors rather than "eat better and exercise more."